-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
MiNK Therapeutics (NASDAQ:INKT) Stock Price Down 0.4%
MiNK Therapeutics (NASDAQ:INKT) Stock Price Down 0.4%
MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) shares traded down 0.4% during mid-day trading on Wednesday . The stock traded as low as $2.50 and last traded at $2.51. 7,858 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 169,116 shares. The stock had previously closed at $2.52.
MiNK Therapeutics Price Performance
The company's 50-day moving average is $2.35 and its 200-day moving average is $2.02.
Get MiNK Therapeutics alerts:MiNK Therapeutics (NASDAQ:INKT – Get Rating) last announced its quarterly earnings results on Thursday, November 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.04. Analysts anticipate that MiNK Therapeutics, Inc. will post -0.84 EPS for the current fiscal year.
Institutional Investors Weigh In On MiNK Therapeutics
An institutional investor recently bought a new position in MiNK Therapeutics stock. First Republic Investment Management Inc. acquired a new position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 81,500 shares of the company's stock, valued at approximately $172,000. First Republic Investment Management Inc. owned approximately 0.24% of MiNK Therapeutics at the end of the most recent reporting period. Institutional investors own 1.07% of the company's stock.MiNK Therapeutics Company Profile
(Get Rating)
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials.
Featured Articles
- Get a free copy of the StockNews.com research report on MiNK Therapeutics (INKT)
- There Is Fundamental Value In Broadcom, And It Yields 3.35%
- Costco vs Amazon: an end of the year showdown
- Discount Retailers Could Make Good Bargain Stocks
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- This Is Why Daktronics Fell 40% In One Day
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) shares traded down 0.4% during mid-day trading on Wednesday . The stock traded as low as $2.50 and last traded at $2.51. 7,858 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 169,116 shares. The stock had previously closed at $2.52.
明克治療公司(納斯達克代碼：iNKT-GET Rating)股價週三午盤下跌0.4%。該股交易價格低至2.50美元，最後報2.51美元。午盤交易中，有7,858股股票易手，較169,116股的平均成交量下降了95%。該股此前收盤價為2.52美元。
MiNK Therapeutics Price Performance
水貂治療公司的價格表現
The company's 50-day moving average is $2.35 and its 200-day moving average is $2.02.
該公司50日移動均線切入位在2.35美元，200日移動均線切入位在2.02美元。
MiNK Therapeutics (NASDAQ:INKT – Get Rating) last announced its quarterly earnings results on Thursday, November 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.04. Analysts anticipate that MiNK Therapeutics, Inc. will post -0.84 EPS for the current fiscal year.
貂皮治療公司(納斯達克代碼：iNKT-GET Rating)上一次公佈季度收益是在11月3日星期四。該公司公佈了該季度每股收益(EPS)(0.19美元)，比普遍預期的(0.23美元)高0.04美元。分析師預計，水貂治療公司本財年的每股收益將達到0.84美元。
Institutional Investors Weigh In On MiNK Therapeutics
機構投資者看好水貂治療公司
MiNK Therapeutics Company Profile
水貂治療公司簡介
(Get Rating)
(獲取評級)
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials.
明克治療公司是一家臨床階段的生物製藥公司，致力於同種異體、現成、不變的自然殺傷T(INKT)細胞療法的發現、開發和商業化，以治療癌症和其他免疫介導性疾病。它的候選產品是AGENT-797，這是一種現成的同種異體藥物，用於iNKT細胞治療和治療各種骨髓瘤疾病，目前處於第一階段臨床試驗。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on MiNK Therapeutics (INKT)
- There Is Fundamental Value In Broadcom, And It Yields 3.35%
- Costco vs Amazon: an end of the year showdown
- Discount Retailers Could Make Good Bargain Stocks
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- This Is Why Daktronics Fell 40% In One Day
- 免費獲取StockNews.com關於水貂治療的研究報告(INKT)
- 博通有基本面價值，收益率為3.35%
- 好市多VS亞馬遜：年底攤牌
- 折扣零售商可以做好的便宜貨
- 輝瑞、強生能否繼續跑贏該指數？
- 這就是為什麼達科電子在一天內下跌了40%
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受水貂治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對水貂治療和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧